Arcutis shares jump after FDA approves drug for chronic skin condition
Investing.com -- Shares in Arcutis Biotherapeutics (NASDAQ:ARQT) surged on Monday after the U.S. Food and Drug Administration approved the use of the drugmaker's treatment for a skin condition called seborrheic dermatitis in patients nine years of age or older.
Seborrheic dermatitis is a common skin condition that causes scaly patches, inflamed skin and stubborn dandruff on oily areas of the body like the face, eyebrows or chest, according to the Mayo Clinic.
The disease impacts over 10 million people in the U.S., California-based Arcutis said.
In a statement released following the close of trading on Friday, the company noted the FDA has made its once-daily roflumilast topical foam -- known as Zoryve --- the first drug approved for seborrheic dermatitis "with a new mechanism of action" in more than two decades. The commercial product is expected to be made available by the end of January, the company added.
Arcutis said a late-stage trial found that Zoryve met its primary efficacy goal, with a success rate of 79.5% on a 5-point assessment scale. A vehicle similar to a placebo was shown to have a success rate of 58%.
Chief Commercial Officer Todd Edwards has said that two of the top three U.S. pharmacy benefit managers are projected to cover the product, Reuters reported.
Related Articles
Arcutis shares jump after FDA approves drug for chronic skin condition
Japan's Nippon Steel to acquire U.S. Steel for $14.9 billion
Exclusive-US lawmakers warn Biden to probe EU targeting of tech firms -letter
